Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 4/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697914 | 0.93 | PPARD (0.38) | PPARDFDPSSMPD1 | |
| SCHEMBL16697323 | 0.85 | FDPS (0.36) | PPARDFDPSSMPD1 | |
| SCHEMBL13515110 | 0.80 | FFAR4 (0.47) | — | |
| SCHEMBL16696821 | 0.77 | CYP3A4 (0.37) | FDPSSMPD1 | |
| SCHEMBL16697204 | 0.74 | FDPS (0.34) | FDPSSMPD1 | |
| SCHEMBL16697104 | 0.74 | FDPS (0.47) | FDPSSMPD1S1PR2S1PR1S1PR3 | |
| SCHEMBL16696995 | 0.73 | SMPD1 (0.36) | FDPSSMPD1PLA2G4A | |
| SCHEMBL16696792 | 0.73 | FDPS (0.33) | FDPSSMPD1 | |
| SCHEMBL7157784 | 0.73 | PLA2G1B (0.39) | — | |
| SCHEMBL2819799 | 0.73 | PPARD (0.39) | PPARDFDPSSMPD1S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441285-B2 | Bifunctional compounds useful as ligands of uranium (VI), methods of synthesising same and uses thereof | AREVA MINES (FR) | 2016-09-13 | — | — | US | disclosed |
| US-20150133688-A1 | BIFUNCTIONAL COMPOUNDS USEFUL AS LIGANDS OF URANIUM (VI), METHODS OF SYNTHESISING SAME AND USES THEREOF | AREVA MINES (FR) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133688-A1 | BIFUNCTIONAL COMPOUNDS USEFUL AS LIGANDS OF URANIUM (VI), METHODS OF SYNTHESISING SAME AND USES THEREOF | URB2, CHRM2, C1S | PPARD 2472/4885FDPS 2645/4885SMPD1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.